MYR GmbH | EU-Startups

Home MYR GmbH

MYR GmbH

Category

Business Description

MYR is the first private German biotech company to successfully take a drug from preclinical development to market. MYR’s lead compound ‘Bulevirtide’, sold under the brand name HepcludexTM, is a first-in-class entry inhibitor for the treatment of the most severe form of viral hepatitis, chronic hepatitis D (HDV).

Based in

Bad Homburg

Tags

Biotechnology, Health Care, Pharmaceutical

Total Funding

No funding announced yet

Founded

2011

Website

http://www.myr-pharma.com/

💡 You're a corporate or investor and looking for startups that are innovating in the same market as MYR GmbH? We're happy to assist you with our Startup Sourcing service.